Company Contents
Quick Facts & Snapshot
Summary
The global atherectomy devices market is in a solid growth phase, driven by rising peripheral arterial disease, device miniaturization, and hospital demand for safer, efficient plaque removal. Market value is projected to reach US$ 1.48 Billion in 2025 and US$ 2.61 Billion by 2032, reflecting an 8.30% CAGR, with leading Atherectomy Devices market companies consolidating share through innovation and partnerships.
Source: Secondary Information and ReportMines Research Team - 2026
Ranking Methodology
The ranking of Atherectomy Devices market companies is based on a multi-factor, weighted-scoring framework combining quantitative and qualitative indicators. Core metrics include 2025 atherectomy-specific revenues, three-year growth, and global installed base across hospitals and ambulatory surgical centers. Technology differentiation is evaluated through portfolio breadth (directional, orbital, rotational, laser, hybrid), intellectual property depth, clinical evidence, and integration with imaging or robotics. Service coverage considers training, technical support, and long-term maintenance contracts, especially in high-volume vascular centers. Strategic momentum is assessed via regulatory approvals, new product launches, key partnerships, and M&A since 2024. Each company is scored on a 0-100 scale across revenue, technology, geographic reach, and strategic execution, with category weights aligned to current buyer priorities. Final rankings reflect composite scores, cross-checked against qualitative interviews with clinicians, procurement leaders, and distributors to validate share trends and perceived competitive positioning.
Top 10 Companies in Atherectomy Devices
Source: Secondary Information and ReportMines Research Team - 2026
Detailed Company Profiles
Boston Scientific Corporation
Boston Scientific is a global medtech leader with a strong footprint in peripheral and coronary interventions, including advanced atherectomy platforms.
Medtronic plc
Medtronic offers a diversified cardiovascular portfolio, with directional and rotational atherectomy solutions embedded in integrated vascular therapy offerings.
Philips (Spectranetics)
Philips Spectranetics specializes in laser atherectomy integrated with image-guided therapy platforms, targeting complex peripheral and coronary lesions.
Cardiovascular Systems Inc. (CSI) – Abbott
CSI, now part of Abbott, focuses on orbital atherectomy devices for highly calcified peripheral and coronary lesions.
Avinger Inc.
Avinger develops image-guided atherectomy catheters designed to improve precision and reduce radiation exposure in peripheral interventions.
Terumo Corporation
Terumo is a Japanese medtech major, offering atherectomy alongside guidewires, balloons, and access products for integrated vascular solutions.
Becton, Dickinson and Company (BD)
BD integrates atherectomy tools within a broader vascular access and interventional specialties portfolio aimed at hospitals and ambulatory centers.
Royal Philips – Peripheral Solutions
Philips Peripheral Solutions complements imaging systems with atherectomy and vascular devices to offer end-to-end image-guided therapy ecosystems.
Straub Medical AG
Straub Medical focuses on mechanical thrombectomy and atherectomy systems, serving vascular specialists in Europe and selected international markets.
Biotronik SE & Co. KG
Biotronik offers atherectomy as part of a broader vascular intervention portfolio including stents and drug-eluting technologies.
SWOT Leaders
Boston Scientific Corporation
SWOT Snapshot
Comprehensive atherectomy portfolio, strong clinical data, and deep relationships with high-volume vascular centers worldwide.
Complex product portfolio can challenge training and inventory management for smaller hospitals and outpatient labs.
Growing adoption of atherectomy in ambulatory surgical centers and global shift toward minimally invasive PAD treatment.
Pricing pressure from competitors and reimbursement scrutiny in mature markets could compress margins over time.
Medtronic plc
SWOT Snapshot
Global brand recognition, broad cardiovascular ecosystem, and integrated solutions spanning access, atherectomy, and stents.
Athrectomy is one of many priorities, potentially diluting focus on rapid innovation and niche indications.
Bundled contracts with payers and IDNs, plus expansion in underpenetrated emerging markets with rising PAD prevalence.
Competition from specialized Atherectomy Devices market companies and regional players with lower-cost offerings.
Philips (Spectranetics)
SWOT Snapshot
Unique laser atherectomy competency tightly linked with imaging platforms and strong presence in complex lesion treatment.
Higher capital and procedure costs may limit adoption in cost-constrained hospitals and emerging markets.
Increasing complexity of PAD cases and demand for image-guided interventions support premium positioning of laser systems.
Technological advances in mechanical systems and reimbursement challenges for high-cost laser procedures.
Atherectomy Devices Market Regional Competitive Landscape
North America remains the largest regional market, driven by high peripheral arterial disease prevalence, established reimbursement, and strong adoption of minimally invasive interventions. Boston Scientific, Medtronic, and Philips (Spectranetics) dominate, while Avinger gains traction in image-guided procedures. Outpatient vascular labs increasingly influence purchasing decisions, favoring Atherectomy Devices market companies offering training and bundled service contracts.
Europe shows steady growth, supported by aging populations and national initiatives to reduce amputations related to peripheral arterial disease. Boston Scientific, Medtronic, and Philips have strong positions, with Straub Medical and Biotronik leveraging local relationships and niche mechanical solutions. Procurement remains price-sensitive, pushing Atherectomy Devices market companies to offer value-based packages and post-market clinical data to secure tenders.
Asia Pacific is the fastest-growing region as cardiovascular risk factors rise in China, India, and Southeast Asia. Terumo benefits from regional familiarity and distribution strength, while Medtronic and Boston Scientific expand through training programs and key opinion leader partnerships. Regulatory diversity and budget constraints require Atherectomy Devices market companies to localize portfolios and adopt tiered pricing strategies.
The Middle East and Africa present smaller but high-potential markets, particularly in Gulf Cooperation Council countries investing in advanced cardiovascular centers. Philips, Boston Scientific, and Straub Medical are visible in flagship hospitals, often via distributor-led models. Successful Atherectomy Devices market companies focus on physician education, on-site proctoring, and integrating atherectomy into comprehensive vascular treatment pathways.
Latin America is emerging with moderate growth, constrained by reimbursement variability and economic volatility. Medtronic, BD, and Biotronik are prominent through integrated vascular portfolios and government tenders. Local distributors play a critical role, and Atherectomy Devices market companies that provide financing options, training support, and robust post-sales service gain competitive advantage in public-sector accounts.
Atherectomy Devices Market Emerging Challengers & Disruptive Start-Ups
Emerging Challengers & Disruptive Start-Ups
Developing low-profile, photo-acoustic atherectomy catheters that selectively target plaque while minimizing vessel wall trauma and distal embolization.
Engineering nano-textured rotational tips designed to improve efficiency in calcified lesions and reduce procedure time in complex PAD cases.
Combining robotic navigation with AI-guided atherectomy planning, enabling more consistent outcomes and reduced radiation for operators and patients.
Offering single-use, cost-optimized atherectomy and thrombectomy kits tailored for budget-constrained hospitals in emerging markets and secondary care centers.
Cloud-based analytics platform that aggregates procedure data across devices, helping Atherectomy Devices market companies demonstrate real-world outcomes and economic value.
Atherectomy Devices Market Future Outlook & Key Success Factors (2026-2032)
From 2025 to 2031, cumulative investments in metro expansions and station safety upgrades are projected to surpass significant amounts. The total market will scale from US$ 2.27 Billionin 2025 to US$ 3.38 Billion by 2031, reflecting a 6.90% CAGR. Winning Atherectomy Devices market companies will share several attributes. First, they will embed native IoT sensors, enabling predictive maintenance contracts that can double recurring revenue within five years. Second, modular design philosophies—interchangeable panels, plug-and-play controllers—will shorten installation windows and appeal to cost-sensitive public operators.
Localization strategies will also define competitive edges. Suppliers that establish regional assembly plants to meet content rules in India, Brazil, or the U.S. are likely to capture bonus points in tenders. Finally, sustainability credentials will move from optional to mandatory. Recyclable composite panels, energy-efficient brushless motors, and life-cycle carbon disclosures will become bid differentiators. In short, the coming decade rewards Atherectomy Devicesmarket companies that marry digital intelligence with manufacturing agility and regulatory foresight.
Frequently Asked Questions
Find answers to common questions about this company report.